<DOC>
	<DOCNO>NCT00612599</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare pharmacodynamics pharmacokinetics biphasic insulin aspart 50 three time day biphasic insulin aspart 70 three time day non-obese obese type 2 diabetes .</brief_summary>
	<brief_title>Comparison Pharmacodynamics Pharmacokinetics Biphasic Insulin Aspart 50 Biphasic Insulin Aspart 70 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes least 12 month Stable glycaemic control , exist treatment least 1 month BMI 2328 kg/m2 ( nonobese ) 3035 kg/m2 ( obese ) HbA1c 9.0 % Willing eat three main meal per day trial period perform SelfMonitoring Blood Glucose ( SBGM ) regularly A history drug abuse alcohol dependence Blood donation within last 3 month Currently treat systemic corticosteroid , Mono Amine Oxidase ( MAO ) inhibitor , betaadrenergic block agent , anabolic steroid drug affect blood glucose Severe , uncontrolled hypertension Proliferative retinopathy maculopathy require acute treatment Pregnancy , breastfeeding , intention become pregnant judge use adequate contraceptive measure ( woman childbearing potential contraceptive pill intra uterine device consider adequate contraceptive method )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>